Synaptive Medical Inc. has announced that Duke University Medical Center has acquired its connected neurosurgery system. Modus V, the cornerstone of the company’s automated robotic and imaging technology, sets a new standard for visual accuracy during surgery and advances minimally invasive cranial and spine procedures.
“Duke is a storied leader in the medical field, including in minimally invasive cranial surgery,” said Peter Wehrly, Synaptive’s CEO. “They have a long history of neurosurgical innovation and thought leadership, and we are proud to see our devices and software made available to their team as they provide patients with best-in-class care.”
Modus V is an automated robotic arm with high-powered digital microscope that provides an unprecedented view of patient anatomy. Using the most powerful optics available on the market today and robotic technology originally developed for the International Space Station, Modus V allows surgeons to perform less invasive procedures with more precision. In some cranial cases, it may allow surgeries that were previously deemed inoperable.
Duke has also acquired Synaptive’s BrightMatter integrated surgical platform. BrightMatter Plan automates the generation of brain tractography imaging, which maps the sensitive white matter tracts that control sight, mobility and other functions in the body. This functionality gives surgeons a dynamic 3D visualization of the brain that may allow for less invasive surgery and potentially safer surgical routes. For patients, less invasive procedures may lead to reduced complications and faster recovery times.
“Among many things, the future for neurosurgery includes the study of the effective use of technology to automate existing manual processes and explore the benefits of adopting robotics solutions that have the potential to result in these procedures being less traumatic for patients and more precise,” said Dr. Patrick Codd, a neurosurgeon at Duke Cancer Center and head of the minimally invasive neurosurgery program.
“Connecting our technology with Duke’s intraoperative MRI provides exciting opportunities to explore how integration may facilitate better surgery outcomes for patients,” said Cameron Piron, Synaptive’s co-founder and president. “Duke’s expertise in glioma surgery, immunology and immunotherapy also makes them ideal partners, and we look forward to collaborating with their neurosurgery team to gain further insight to fuel our developments.”
The Preston Robert Tisch Brain Tumor Center at Duke is internationally known for its advancements in surgical care and research and treats approximately 700 patients per year.